RxTrials Institute Drug Pipeline Alert

NexMed announced that Novartis Pharma AG completed patient enrollment for two Phase III clinical trials for NM100060, a topical treatment for nail fungus.

NM100060 is a topical application of Lamisil (terbinafine), formulated with terbinafine and NexMed’s patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides, NexMed said.

NexMed entered into an agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060, NexMed said.